Journal
HEART LUNG AND CIRCULATION
Volume 23, Issue 4, Pages 299-302Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.hlc.2013.10.088
Keywords
HIV; Hypertension; Pulmonary; Aetiology; Therapeutics
Categories
Funding
- National Natural Science Foundation of China [81360037]
- Natural Science Foundation of Yunnan [2012FB009]
- Talent Program, Yunnan Province, China
- Monash Professorial Fellowship, Monash University, Australia
Ask authors/readers for more resources
Pulmonary arterial hypertension (PAH) is an infrequent but nevertheless serious life threatening severe complication of human immunodeficiency virus (HIV) infection. In today's era of antiretroviral therapy (ART), the mortality of HIV patients has greatly reduced due to improved immune function and fewer opportunistic infections. However, these patients have an increased incidence of PAH. In this review, we will mainly discuss HIV-related pulmonary arterial hypertension (HRPH) in terms of the epidemiology, pathogenesis, clinical characteristics and treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available